Catalyst
Slingshot members are tracking this event:
Following CLEAR CVOT, Esperion Therapeutics (ESPR) to submit New Drug Application to FDA for reduction of risk of cardiovascular disease, MAA to EMA, by 2022
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Future Window:
Jan 01, 2022 - Dec 31, 2022
Related Projects
- Understanding the impact of tofacitinib safety data that was released in January 2021 on JAK prescribing behavior in the U.S for RA and PsA. LLY, PFE, ABBV Executed On: Aug 24, 2021 at 05:00 PM EDT
Related Keywords
Cardiovascular Safety, Fda Review, Nda, Ema, Maa Submission, Clear Cvot
